HomeCompareLVTX vs PEP

LVTX vs PEP: Dividend Comparison 2026

LVTX yields 114.94% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LVTX wins by $6.90M in total portfolio value
10 years
LVTX
LVTX
● Live price
114.94%
Share price
$1.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.05M
Annual income
$2,599,161.52
Full LVTX calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — LVTX vs PEP

📍 LVTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLVTXPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LVTX + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LVTX pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LVTX
Annual income on $10K today (after 15% tax)
$9,770.11/yr
After 10yr DRIP, annual income (after tax)
$2,209,287.29/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, LVTX beats the other by $2,155,371.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LVTX + PEP for your $10,000?

LVTX: 50%PEP: 50%
100% PEP50/50100% LVTX
Portfolio after 10yr
$3.60M
Annual income
$1,331,296.01/yr
Blended yield
37.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

LVTX
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$3.75
+115.5% upside vs current
Range: $1.50 — $6.00
Altman Z
-4.7
Piotroski
1/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LVTX buys
0
PEP buys
0
No recent congressional trades found for LVTX or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLVTXPEP
Forward yield114.94%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$7.05M$144.7K
Annual income after 10y$2,599,161.52$63,430.49
Total dividends collected$6.38M$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold
Analyst price target$3.75$172.43

Year-by-year: LVTX vs PEP ($10,000, DRIP)

YearLVTX PortfolioLVTX Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$22,194$11,494.25$10,854$514.44+$11.3KLVTX
2$47,590$23,841.72$11,982$758.21+$35.6KLVTX
3$98,699$47,777.67$13,526$1,136.44+$85.2KLVTX
4$198,214$92,606.18$15,727$1,741.93+$182.5KLVTX
5$385,900$173,811.71$19,012$2,750.28+$366.9KLVTX
6$729,168$316,254.64$24,173$4,514.44+$705.0KLVTX
7$1,338,687$558,477.43$32,789$7,793.80+$1.31MLVTX
8$2,390,633$958,237.97$48,258$14,354.51+$2.34MLVTX
9$4,157,254$1,599,276.16$78,586$28,686.63+$4.08MLVTX
10$7,047,423$2,599,161.52$144,688$63,430.49+$6.90MLVTX

LVTX vs PEP: Complete Analysis 2026

LVTXStock

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Full LVTX Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this LVTX vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LVTX vs SCHDLVTX vs JEPILVTX vs OLVTX vs KOLVTX vs MAINLVTX vs MOLVTX vs PMLVTX vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.